{"doi":"10.3390/molecules25071596","title":"Pre-Clinical Investigation of Keratose as an Excipient of Drug Coated Balloons","abstract":"Background: Drug-coated balloons (DCBs), which deliver anti-proliferative drugs with the aid of excipients, have emerged as a new endovascular therapy for the treatment of peripheral arterial disease. In this study, we evaluated the use of keratose (KOS) as a novel DCB-coating excipient to deliver and retain paclitaxel. Methods: A custom coating method was developed to deposit KOS and paclitaxel on uncoated angioplasty balloons. The retention of the KOS-paclitaxel coating, in comparison to a commercially available DCB, was evaluated using a novel vascular-motion simulating ex vivo flow model at 1 h and 3 days. Additionally, the locoregional biological response of the KOS-paclitaxel coating was evaluated in a rabbit ilio-femoral injury model at 14 days. Results: The KOS coating exhibited greater retention of the paclitaxel at 3 days under pulsatile conditions with vascular motion as compared to the commercially available DCB (14.89 ± 4.12 ng/mg vs. 0.60 ± 0.26 ng/mg, p = 0.018). Histological analysis of the KOS–paclitaxel-treated arteries demonstrated a significant reduction in neointimal thickness as compared to the uncoated balloons, KOS-only balloon and paclitaxel-only balloon. Conclusions: The ability to enhance drug delivery and retention in targeted arterial segments can ultimately improve clinical peripheral endovascular outcomes.","journal":"Molecules","year":2020,"id":81039,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":14,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9642,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":419732,"name":"Megan M. Erwin","orcid":"0000-0002-7014-0856","position":1,"is_corresponding":false},{"id":419733,"name":"Claire V. Cawthon","orcid":"0000-0002-9120-5479","position":2,"is_corresponding":false},{"id":421067,"name":"Carson Schaff","orcid":null,"position":3,"is_corresponding":false},{"id":421068,"name":"Nathaniel Fedor","orcid":null,"position":4,"is_corresponding":false},{"id":421069,"name":"Trevor Rayl","orcid":null,"position":5,"is_corresponding":false},{"id":421070,"name":"Onree Wilson","orcid":null,"position":6,"is_corresponding":false},{"id":419734,"name":"Uwe Christians","orcid":"0000-0001-7297-147X","position":7,"is_corresponding":false},{"id":419735,"name":"Thomas C. Register","orcid":"0000-0002-4078-0166","position":8,"is_corresponding":false},{"id":370490,"name":"Randolph L. Geary","orcid":null,"position":9,"is_corresponding":false},{"id":419736,"name":"Justin M. Saul","orcid":"0000-0002-5771-4958","position":10,"is_corresponding":false},{"id":419737,"name":"Saami K. Yazdani","orcid":"0000-0002-9719-6382","position":11,"is_corresponding":false},{"id":421066,"name":"Emily Goel","orcid":null,"position":0,"is_corresponding":true}],"reference_count":52,"raw_metadata":null,"created_at":"2026-07-18T21:52:34.401799Z","pmid":"32244375","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}